Washington, D.C. 20549









Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


October 12, 2015




 (Exact name of Registrant as specified in its charter)



Novo Allé 

DK- 2880, Bagsvaerd 


(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F


Form 20-F [X]           Form 40-F [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes [  ]            No [X]


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________






Novo Nordisk A/S – Share repurchase programme


Bagsværd, Denmark, 12 October 2015 – On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.


Under the programme initiated 30 April 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 9.3 billion in the period from 30 April 2015 to 27 October 2015.


Since the announcement as of 1 October 2015, the following transactions have been made under the programme:


  Number of
B shares
purchase price
value, DKK
Accumulated, last announcement 20,962,200   7,939,264,756
1 October 2015 205,000 364.31 74,683,222
2 October 2015 215,000 361.10 77,636,801
5 October 2015 200,000 365.85 73,170,340
6 October 2015 195,000 368.08 71,774,996
7 October 2015 205,000 361.95 74,199,463
8 October 2015 220,000 358.79 78,934,064
9 October 2015 215,000 357.16 76,790,239
Accumulated under the programme 22,417,200   8,466,453,880


With the transactions stated above, Novo Nordisk owns a total of 42,185,571 B shares of DKK 0.20, corresponding to 1.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.



Page 2 of 2



Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 9 October 2015, Novo Nordisk has repurchased a total of 33,595,104 B shares equal to a transaction value of DKK 12,166,453,551.



Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube



Further information

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje

+45 3079 8519

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com






Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd



+45 4444 8888




CVR no:

24 25 67 90

    Company announcement No 62 / 2015







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.


Date: October 12, 2015




Lars Rebien Sørensen,

Chief Executive Officer